Recruiting NCT06930677

NCT06930677 Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

◆ AI Clinical Summary

Plain-language summary for patients

Clinical Trial Summary
NCT ID	NCT06930677
Status	Recruiting
Phase	—
Sponsor	Next Biomedical Co., Ltd.
Condition	Knee Osteoarthritis (Knee OA)
Study Type	INTERVENTIONAL
Enrollment	72 participants
Start Date	2025-04-17
Primary Completion	2027-02

Trial Parameters

Condition Knee Osteoarthritis (Knee OA)

Sponsor Next Biomedical Co., Ltd.

Study Type INTERVENTIONAL

Phase N/A

Enrollment 72

Sex ALL

Min Age 50 Years

Max Age N/A

Start Date 2025-04-17

Completion 2027-02

Interventions

embolization therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Your Age

Your Sex

Brief Summary

Study in patients with knee osteoarthritis treated by embolization using NBGM200

Eligibility Criteria

Inclusion Criteria: * Osteoarthritis proven by MR-imaging Exclusion Criteria: * Current local infection * Life expectancy less than 6 months

Related Trials

NCT06930677

Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

View Trial →

NCT07464080

Advanced Brain Imaging-TKA (fMRI-TKA)

View Trial →

NCT06611618

Analysis of the Loss of Muscle Force, Power and Motor Control to Predict the Risk of Falls in Patien

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE KNEE OSTEOARTHRITIS (KNEE OA) TRIALS

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology